Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesTRUFF +2.37% 5-Year Yield-on-Cost % is 0.00 as of Aug. 13, 2026. The stock has 3 warning signs investors should review. Among 511 Drug Manufacturers companies, Rhelion Life Sciences ranks worse than 195694.52% on this metric.
Rhelion Life Sciences's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Rhelion Life Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:
TRUFF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.28 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Rhelion Life Sciences (OTCPK:TRUFF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Rhelion Life Sciences 5-Year Yield-on-Cost % Related Terms
TRUFF vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's 5-Year Yield-on-Cost % falls into.
Rhelion Life Sciences 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Rhelion Life Sciences (TRUFF) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Rhelion Life Sciences and its competitors. According to the industry distribution chart, Rhelion Life Sciences ranks #999999 out of 511 companies in the Drug Manufacturers industry.
Is Rhelion Life Sciences' 5-Year Yield-on-Cost % too high?
Rhelion Life Sciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Rhelion Life Sciences ranks #999999 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rhelion Life Sciences' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #999999 out of 511 companies for 5-Year Yield-on-Cost %. This places Rhelion Life Sciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (TRUFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 25.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Rhelion Life Sciences (TRUFF), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRUFF has been successfully added to your 
